|1.||Delzell, Elizabeth: 4 articles (11/2009 - 09/2005)|
|2.||Swenberg, J A: 4 articles (06/2001 - 01/2000)|
|3.||Sathiakumar, Nalini: 3 articles (11/2009 - 09/2005)|
|4.||Zhang, L: 3 articles (10/2001 - 01/2000)|
|5.||Yang, Jen Ming: 2 articles (01/2014 - 08/2012)|
|6.||Huang, Huei Tsz: 2 articles (01/2014 - 08/2012)|
|7.||Valdez-Flores, Ciriaco: 2 articles (08/2011 - 03/2007)|
|8.||Sielken, Robert L: 2 articles (08/2011 - 03/2007)|
|9.||Kirman, Christopher R: 2 articles (10/2010 - 03/2007)|
|10.||Gargas, Michael L: 2 articles (10/2010 - 03/2007)|
|1.||Brain Ischemia (Cerebral Ischemia)
11/01/2000 - "For the specimens containing surface-treated continuous fibers in a cross-ply arrangement that had demonstrated a substantial improvement in the modulus of rupture, there was no evidence of fiber buckling, and the layer of butadiene styrene was consistently thin and even in comparison to weaker specimens. "
05/01/2005 - "Previous studies have focused on the types of genetic damage and tumors found after long-term exposure of rodents to butadiene. "
06/01/2001 - "The major factors hampering the assessment of the available results are (i) possible misclassification of lymphoid and haematopoietic neoplasms, (ii) limitations in the assessment of past exposure (with the exception of the study of SBR workers) and (iii) a potential confounding effect of agents other than butadiene. "
10/01/2000 - "Thus, the GSTT1-1 genotype is suspected to confer decreased or increased risk of cancer in relation to the source of exposure; in vitro studies, mostly conducted on metabolites of butadiene, confirm the protective action of GSTT1-1, whereas, thus far, experimental studies prove that the increasing risk is limited."
01/01/1999 - "The model is demonstrated by means of fitting the mortality and tumor incidence data from the second NTP mice study on butadiene to a Weibull model and to the linear, so-called, one-hit model. "
01/01/1993 - "The studies in mice show a good correspondence with the reported associations between occupational exposure to butadiene and excess mortality from lymphatic and haematopoietic cancers; mice are thus a better experimental surrogate for humans. "
09/01/2005 - "This study found a positive association between butadiene and leukemia that was not explained by exposure to other agents examined."
06/01/2001 - "Leukemia was clearly associated with increasing estimated butadiene exposure in the SBR study, but not in the monomer industry study. "
05/01/1997 - "Results from epidemiologic studies of butadiene-exposed workers are somewhat inconsistent, but the largest study with the best exposure assessment found the largest relative risk for leukemia. "
03/01/1993 - "Only one study has evaluated directly the relation between estimates of butadiene exposure and leukemia, and this investigation reports a positive association. "
10/01/1992 - "The results of this study support the hypothesis that exposure to butadiene is associated with the risk of leukemia. "
01/01/1993 - "Stop-exposure studies revealed that the atmospheric concentration of butadiene was a greater contributing factor to the development of lymphomas than was duration of exposure. "
05/01/2000 - "Using the poly-3 quantal response method to adjust for the extensive and early development of lethal lymphomas in butadiene-exposed mice provided a means of obtaining a better representation of dose-response relationships for late-developing tumors induced by this chemical. "
12/01/2008 - "This report shows that Notch1 is a prevalent and major mutational target for 2',3'-dideoxycytidine and butadiene-induced lymphoma."
07/15/1996 - "To identify potential tumor suppressor genes involved in lymphoma development, we generated allelotypes of 16 2',3'-dideoxycytidine (ddC and 31 1,3-butadiene (BD)-induced lymphomas from C57BL/6 x C3H/He F1 (hereafter called B6C3F1) mice. "
05/01/2000 - "Söderkvist, Inactivation of p16(INK4a)-alpha, p16(INK4a)-beta and p15(INK4b) genes in 2', 3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas, Oncogene 16 (1998) 803-808), indicating the involvement of pRb pathway in lymphomagenesis. "
|2.||U 0126 (UO 126)
|5.||Biological Markers (Surrogate Marker)
|8.||Hypoxanthine Phosphoribosyltransferase (Hypoxanthine Guanine Phosphoribosyltransferase)
|3.||Drug Therapy (Chemotherapy)